Article Text

Download PDFPDF
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

Statistics from Altmetric.com

Footnotes

  • Competing interests MC and PR are consultants and/or members of the Speaker Bureau at AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and Novartis.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.